点击注册小程序 查看完整报告 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 深化"三链融合"，加速推进国际化布局 公司持续深化"三链融合"，推动业务由供应链贸易向产业链运营和供应链服务转型升级。公司通过成立合资公 司、股权换商权等方式，开拓焦煤、焦炭全产业链布局，拓展光伏铝型材加工业务，开拓电解铝、氧化铝等业 务。同时公司落地山东日照国贸物流园项目，以"公铁水仓+智慧物流园"为核心，开展黑色、有色及能化等大 宗商品的综合物流服务。国际化发展方面，公司正式成立国际化发展部，同时已与170多个国家和地区的9万余 家产业链上下游企业建立稳定的合作关系，形成覆盖全球大宗商品资源的渠道网络。2024年，公司在海外地区 实现营收662亿元，同比增长0.67%，对应营收占比同比提升4.6pct至18.7%。 事件： 公司发布 ...

Core Viewpoint - The company demonstrated strong operational resilience in its 2024 annual report, achieving a revenue of 2.012 billion yuan and a net profit of 302 million yuan, with a significant year-on-year growth in its self-owned business segment [2] Group 1: Financial Performance - The company reported a revenue of 2.012 billion yuan for 2024, with a net profit attributable to shareholders of 302 million yuan and a non-recurring net profit of 287 million yuan [2] - Revenue from the self-owned business segment reached 1.672 billion yuan, marking a year-on-year increase of 26.13% [2] Group 2: R&D and Technological Advancements - The company invested 338 million yuan in R&D for 2024, representing a year-on-year increase of 3.84% and accounting for 16.80% of total revenue [2] - The company has established a humanized antibody technology platform and integrated AI into the development of bioactive raw materials [3] Group 3: Product Development and Market Expansion - The company added 15 new chemical luminescence testing reagent projects, bringing the total to 178 registered projects by the end of the reporting period [3] - In the first quarter of 2025, the company added 6 more projects, increasing the total to 184 [3] - The company achieved a revenue of 250 million yuan from overseas self-owned business, reflecting a year-on-year growth of 64.78% [3] Group 4: Automation and Smart Solutions - The company developed the iTLA Max laboratory automation system, which integrates AI technology and can process up to 1,200 sample tubes per hour [3] - The automation system connects various instruments and utilizes intelligent robots for automatic supply addition [3] Group 5: International Market Performance - In the first quarter of 2025, the company added 283 new installations overseas, representing a year-on-year increase of 92.52% [3] - The overseas market generated a revenue of 52.3813 million yuan from chemical luminescence business, showing a year-on-year growth of 56.31% [3]

Core Viewpoint - The company, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., has announced its first-quarter report for 2025, confirming the accuracy and completeness of the financial information disclosed [2][24]. Financial Data - The first-quarter report has not been audited [3][7]. - There are no adjustments or restatements required for previous accounting data [4]. - The company does not have any non-recurring profit and loss items [4]. Shareholder Information - The total number of ordinary shareholders and the situation of the top ten shareholders have been disclosed, with no changes reported in the lending of shares [6]. Board Meeting - The sixth board meeting of the company was held on April 24, 2025, with all seven directors participating and approving the first-quarter report [8][9]. - The board also approved an adjustment to the capital increase plan for its wholly-owned subsidiary, Tian Dao Pharmaceutical (Hong Kong) Co., Ltd., reducing the amount from USD 105 million to USD 31.92 million [11][12]. Subsidiary Capital Increase - The capital increase is aimed at expanding the sales and marketing network in the EU and other global markets [17][18]. - The adjustment to the capital increase plan was made in response to external market conditions and the company's global business development needs [18][22]. Product Approval - The company's subsidiary, Shenzhen Tian Dao Pharmaceutical Co., Ltd., received approval from the South African Health Products Regulatory Authority for its Enoxaparin Sodium Injection [25]. - This approval allows the company to sell its Enoxaparin Sodium products in the South African market, enhancing its global market share [26][28].

Core Insights - The company, Langjin Technology, reported a revenue of 881 million yuan for the year 2024, demonstrating resilience amid a complex economic environment through technological innovation and international expansion [1][2] Group 1: Business Performance - The rail transit vehicle air conditioning segment generated revenue of 584 million yuan, marking a year-on-year growth of 14.18%, accounting for 66.29% of total revenue [1] - The company successfully secured major domestic projects, including the Shanghai Metro Line 13 East Extension and Shenzhen Metro Line 12 Phase II, while also completing overseas orders in Italy and Romania [1] - By the end of 2024, the company had 30,000 rail transit air conditioning units operating online domestically, achieving annual electricity savings of 375 million kWh and reducing carbon dioxide emissions by 375,000 tons [1] Group 2: Technological Development - In the new energy and intelligent thermal management sector, the company is expanding its technology development for integrated thermal management systems, particularly for commercial vehicles [2] - The company has delivered cooling products for several major renewable energy and energy storage projects, with cumulative shipments exceeding 35 GWh [2] Group 3: Future Strategy - For 2025, the company plans to focus on three main areas: rail transit, new energy, and energy storage, with an emphasis on expanding the new energy commercial vehicle market [2] - The company aims to enhance capital operations through methods such as share issuance and strategic partnerships to support technological research and market expansion [2]

Core Insights - The company reported a total revenue of 3.398 billion yuan in 2024, representing a year-on-year growth of 37.06%, while net profit decreased by 8.14% to 197 million yuan, indicating challenges in cost control and profitability [1] - The company specializes in the research, production, and sales of power line components and special cables, with notable performance in the new energy electric vehicle charging connection products sector [1] Revenue Breakdown - The power line component business achieved revenue of 2.221 billion yuan, a year-on-year increase of 32.90%, driven by deepening cooperation with existing customers and expanding into new markets [4] - The special cable business generated revenue of 1.166 billion yuan, growing by 45.09%, with new energy electric vehicle charging products emerging as a significant growth driver [5] International Expansion - The company is advancing its international strategy, with the Thailand factory generating revenue of 903 million yuan, a year-on-year increase of 56.48%, enhancing production efficiency through smart and automated manufacturing [7] - The international expansion presents challenges, including operational costs and competition in the global market, necessitating improvements in brand influence and market penetration [7]

Core Insights - In 2024, Zhifei Biological achieved a revenue of 26.07 billion yuan and a net profit of 2.018 billion yuan despite industry challenges, showcasing its resilience and long-term development potential [1][2][3] Financial Performance - The company reported a 14.98% year-on-year increase in revenue from self-developed products, totaling 1.182 billion yuan, while agency products faced significant demand fluctuations, with a 95.49% drop in the issuance of Merck's quadrivalent HPV vaccine [2][3] - Accounts receivable decreased from 27.059 billion yuan at the beginning of 2024 to 14.645 billion yuan in Q1 2025, indicating effective financial risk management [3] - The net cash flow from operating activities in Q1 2025 was 304 million yuan, a 107.12% increase year-on-year, reflecting a shift from expansion to refined operations [3] Strategic Initiatives - Zhifei Biological restructured core partnerships to enhance market resilience, extending the exclusive distribution rights for the shingles vaccine with GSK until 2035 and exploring a 10-year collaboration for RSV vaccines [2][3] - The company is adjusting the delivery schedule for Merck's products to optimize inventory management while meeting consumer demand [2][3] Research and Development - In 2024, R&D investment reached 1.391 billion yuan, with cumulative investment exceeding 5.1 billion yuan over five years, leading to significant advancements in its innovation pipeline [4][5] - The company has 34 self-developed projects, with 19 in clinical and registration stages, indicating a potential peak in product launches in the next 3-5 years [7] International Expansion - Zhifei Biological's overseas operations are gaining traction, with its tuberculosis diagnostic reagent "Yika" approved for use in Indonesia and other markets, and the 23-valent pneumonia vaccine receiving GMP certification in the Philippines [6][7] - The company is positioned to benefit from the approval of male indications for Merck's quadrivalent and nine-valent HPV vaccines, expanding its market reach [6][7] Future Outlook - The company aims to continue its commitment to social benefits while pursuing technological innovation and market promotion, positioning itself to play a significant role in public health and the vaccine industry [7][8]

Core Viewpoint - Shanghai Automotive Parts achieved significant growth in 2024, with a revenue of 2.15 billion and a net profit of 189 million, reflecting year-on-year increases of 12.66% and 17.32% respectively [2] Group 1: Financial Performance - The company reported a revenue of 2.15 billion, marking a year-on-year growth of 12.66% [2] - The net profit attributable to shareholders was 189 million, representing a year-on-year increase of 17.32% [2] - A cash dividend of 3 yuan per 10 shares (including tax) is proposed for shareholders [2] Group 2: Business Segments - The automotive thermal management system products generated sales of 1.714 billion, up 15.34% year-on-year [2] - The automotive engine system products achieved sales of 387 million, reflecting a year-on-year increase of 7.08% [2] Group 3: Customer Base and International Sales - The company has established a healthy customer structure, supplying major clients such as Volkswagen, General Motors, and Toyota [3] - In 2024, international sales reached 913 million, accounting for 42.47% of total revenue, with a year-on-year growth of 59.83% [3] - The company has secured a global project for fuel distribution pipes with an overseas client, with an expected total sales amount exceeding 500 million over the project lifecycle [3] Group 4: International Expansion - The Mexican subsidiary generated approximately 290 million in sales, enhancing the company's ability to supply North and South American clients [3] - A Moroccan subsidiary is under construction to support European and African markets [3] Group 5: Future Developments - The company plans to actively develop hydrogen fuel distribution pipes for automotive applications [3] - In the thermal management system segment, the company aims to enhance integrated supply capabilities and explore modular supply markets [4] - The company has secured contracts for valve assembly products with clients like FAW-Volkswagen and plans to increase R&D efforts in system integration and modular supply [4]

投资建议：公司作为工程机械行业龙头企业，国际化、电动化等布局领先，产品、渠道、服务端优势明 显，拳头产品挖机地位稳固竞争力强，后续随国内行业需求筑底回升、行业更新周期逐渐来临，海外市 场继续保持结构化增长，公司收入端、业绩端表现有望加速上行。预计公司2025-2027 年分别实现归母 净利润85、103、118 亿元，对应pe 分别为19/16/14 倍，维持"推荐"评级。 风险提示：贸易摩擦加剧风险、汇率波动风险、海外市场需求不及预期风险、原材料价格波动等。 挖机龙头地位稳固，充分受益于土方机械的相对优势。报告期内，公司挖机市场份额持续提升。拆分收 入看，24 全年公司挖机、混凝土机械、起重机械、路面机械、桩工机械分别实现收入303.74、143.68、 131.15、30.01、20.76 亿元，分别同比+9.9%、-6.2%、+0.9%、+20.7%、-0.4%。挖机国内市场第14 年 蝉联国内销量冠军，混凝土机械连续 14 年蝉联全球第一品牌。公司挖机龙头地位稳固，有望充分受益 于本轮国内工程机械周期上行。 事件：公司发布2024 年年报，全年实现营收784 亿，同比+5.9%；归母净利润59.75 ...

出品｜搜狐财经 作者｜柴鑫洋 编辑｜李文贤 蜜雪冰城、霸王茶姬等奶茶品牌已经先行一步出海，饮料企业也开始踏上探索海外市场的征程。 东鹏饮料近日也向港交所递表，意在为国际化布局铺路。在此前，东鹏饮料在2021年5月就已经在上交所正式登陆 A 股市场。 中国食品产业分析师朱丹蓬认为，'A+H股'上市的战略，是为了国际化布局铺垫，港股是很多中国品牌布局国际化的重要桥梁和契机。 财报显示，东鹏饮料在2024年实现营业收入158.39亿元，同比增长40.63%；归属于上市公司股东的净利润33.27亿元，同比增长63.09%。 福建华策品牌定位咨询创始人詹军豪表示，海外市场拓展也面临许多困难，如文化差异、市场竞争激烈、供应链建设难度大等。东鹏饮料需通过深入市场 调研、加强本土化运营、建立本地供应链等方式，克服这些阻力，实现品牌的国际化发展。 东鹏饮料赴港二次上市，海外扩张提速 近日，东鹏饮料披露的公告显示，正式向港交所递交招股说明书，华泰国际、摩根士丹利和瑞银国际担任联席保荐人。 对于港股上市的原因，东鹏饮料表示是为进一步提高公司的资本实力和综合竞争力，提升公司国际化品牌形象，满足公司国际业务发展需要，深入推进公 司全球 ...

Group 1 - Heng Rui Pharma appointed Ms. Feng Ji as President and Chief Operating Officer, responsible for company management, while former President Dai Hongbin became Vice Chairman [2] - Ms. Feng Ji has over 30 years of experience in the pharmaceutical industry, having worked at Shanghai Renji Hospital, Novartis, Amgen, and AstraZeneca, with a strong background in sales, marketing, and international business operations [2] - The appointment comes at a critical time as Heng Rui Pharma aims to enhance its international presence, having submitted its application to the Hong Kong Stock Exchange on January 6 [2] Group 2 - Heng Rui Pharma has been focusing on the oncology field but is increasingly expanding into chronic disease areas, with 47 innovative pipelines in non-oncology fields, surpassing the number of oncology products in development [2] - Since 2023, the company has accelerated the launch of non-oncology innovative drugs in China, with nine new drugs including Henggrelin, Aimabuxitin, and others covering various fields such as metabolism, cardiovascular, and neuroscience [3] - Industry insiders believe that Ms. Feng Ji's extensive experience in chronic disease will facilitate Heng Rui's rapid expansion in the non-oncology sector [3]